logo-loader
viewTissue Regenix Group PLC

Tissue Regenix sees revenues double in ‘transformational’ first half

Strong sales in its GBM-V and DermaPure divisions sent revenues 118% higher, while the recent £25mln acquisition of CellRight gives it reason to be excited

operating theatre
The increased revenues helped Tissue to narrow its loss after tax to £4.77mln

Tissue Regenix Group PLC (LON:TRX) saw revenues double in the first half of the year, driven by a strong performance of its GBM-V multi-tissue bank and higher sales of its DermaPure wound treatments.

Total revenues at the medical devices firm grew 118% in the six months ended 30 June to £1.37mln (H1 2016: £631,000).

Revenues up, losses down

The increased revenues helped Tissue to narrow its loss after tax to £4.77mln (H1 2016: £5.16mln).

"We are pleased to be able to report continued revenue growth for Tissue Regenix. Our strategy to grow DermaPure sales in the US drove revenue growth by 118% in the first half of 2017,” said chief executive Antony Odell.

In August, after period end, Tissue raised £40mln from investors, of which £25mln was used to complete the “transformational” acquisition of CellRight Technologies.

READ: TRX confirms US$30mln acquisition of CellRight

Following the fundraise, Tissue currently has just over £20mln in the bank.

“With the cash resources now available, investment into the ongoing commercial development of the group will continue and the board is confident this will deliver increased shareholder value,” Odell added.

Tissue said the initial benefits of its first acquisition are starting to be seen and it is now on the lookout for ways to exploit its resources once again in order to build market share and increase its international presence.

OrthoPure XT in CE approval process

The company also has its soft tissue injury product, dCell OrthoPure XT, which is currently progressing through the CE mark regulatory system which will pave the way for it to be sold in Europe.

Due to changes in the approval process, the launch timeline has been pushed back  although Tissue is working closely with the regulatory bodies to “expedite a route to market”.

Tissue shares closed 1.3% higher at 11.4p on Thursday.

Quick facts: Tissue Regenix Group PLC

Price: 0.65 GBX

AIM:TRX
Market: AIM
Market Cap: £7.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read